Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
Kelly
Deanna L
DL
Kreyenbuhl
Julie
J
Love
Raymond C
RC
Van-Duong
Quynh
Q
Conley
Robert R
RR
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D001786:Blood Glucose / Q000378:metabolism*; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D012189:Retrospective Studies; D012306:Risk; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D001786:Blood Glucose; D003987:Dibenzothiazepines; D014280:Triglycerides; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D010890:Pirenzepine; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine